# EDGAR Filing Document

**Accession Number:** 0001900201
**File Stem:** 0001900201-25-000008
**Filing Date:** 2025-10
**Character Count:** 9057
**Document Hash:** 89a8feae9bc67e78c9b286e945beac26
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001900201-25-000008.hdr.sgml**: 20251029

**ACCESSION NUMBER**: 0001900201-25-000008

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251028

**FILED AS OF DATE**: 20251029

**DATE AS OF CHANGE**: 20251029

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Catalyst4, Inc.
- **CENTRAL INDEX KEY:** 0001900201

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42914
- **FILM NUMBER:** 251430197

**BUSINESS ADDRESS:**
- **STREET 1:** 555 BRYANT STREET, NO. 376
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301
- **BUSINESS PHONE:** 650-812-2614

**MAIL ADDRESS:**
- **STREET 1:** 555 BRYANT STREET, NO. 376
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MapLight Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001770069
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 832163243
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 800 CHESAPEAKE DRIVE
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063
- **BUSINESS PHONE:** 650-839-4360

**MAIL ADDRESS:**
- **STREET 1:** 800 CHESAPEAKE DRIVE
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Alvarado Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20190307

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Catalyst4, Inc.<br><sub>(Last) (First) (Middle)</sub><br>555 BRYANT STREET #376<br><sub>(Street)</sub><br>PALO ALTO, CA 94301<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-10-28 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>MapLight Therapeutics, Inc. [ MLPT ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Voting Common Stock | 2025-10-28 |  | C |  | 14256288 | A | <sup>(1)</sup> | 14256288 | I | See footnote<sup>(2)</sup> |
| Voting Common Stock | 2025-10-28 |  | P |  | 5441176 | A | $17 | 19697464 | I | See footnote<sup>(2)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Series A Preferred Stock | <sup>(3)</sup> | 2025-10-28 |  | C |  |  | 148809 | <sup>(3)</sup> | <sup>(3)</sup> | Voting Common Stock | 148809 | <sup>(3)</sup> | 0 | I | See footnote<sup>(2)</sup> |
| Series A-1 Preferred Stock | <sup>(4)</sup> | 2025-10-28 |  | C |  |  | 444846 | <sup>(4)</sup> | <sup>(4)</sup> | Voting Common Stock | 444846 | <sup>(4)</sup> | 0 | I | See footnote<sup>(2)</sup> |
| Series B Preferred Stock | <sup>(5)</sup> | 2025-10-28 |  | C |  |  | 1263768 | <sup>(5)</sup> | <sup>(5)</sup> | Voting Common Stock | 1263768 | <sup>(5)</sup> | 0 | I | See footnote<sup>(2)</sup> |
| Series B-1 Preferred Stock | <sup>(6)</sup> | 2025-10-28 |  | C |  |  | 275148 | <sup>(6)</sup> | <sup>(6)</sup> | Voting Common Stock | 275148 | <sup>(6)</sup> | 0 | I | See footnote<sup>(2)</sup> |
| Series C Preferred Stock | <sup>(7)</sup> | 2025-10-28 |  | C |  |  | 5444807 | <sup>(7)</sup> | <sup>(7)</sup> | Voting Common Stock | 5444807 | <sup>(7)</sup> | 0 | I | See footnote<sup>(2)</sup> |
| Series D Preferred Stock | <sup>(8)</sup> | 2025-10-28 |  | C |  |  | 6678910 | <sup>(8)</sup> | <sup>(8)</sup> | Voting Common Stock | 6678910 | <sup>(8)</sup> | 0 | I | See footnote<sup>(2)</sup> |

---

### Footnotes:

(1) The Series A, A-1, B, B-1, C and D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

(2) The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.

(3) The Series A Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

(4) The Series A-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

(5) The Series B Preferred Stock is convertible on a 1-for-16.8 basis into voting common stock at any time at the holder's election and will convert automatically upon the closing of the Issuer's initial public offering and has no expiration date.

(6) The Series B-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

(7) The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

(8) The Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

**Signature:** /s/ Robert Brown  
**Date:** 2025-10-29

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**